Category: Press Release

Download PDF Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 20, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec. “We are pleased to regain rights for AV-203 as we believe in the potential of this innovative therapy and

Download PDF – Company ends 2013 with $118M in cash1 – – Focuses internal R&D investment on AV-380 in cachexia – – Intends to advance clinical-stage assets through strategic partnering – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 13, 2014– AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance. “With the cost-containment measures implemented in

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 4, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company’s financial results as well as provide an update on strategy for 2014 on Thursday, March

Download PDF Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014 CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Feb. 14, 2014– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozanib. Tivozanib is an

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 30, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO previously announced that enrollment in this study had been slower

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 13, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. BATON-CRC, led by Astellas, is an open-label,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2013– AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results. “We continue to execute on the strategy we outlined earlier this year, focusing our resources where the unique insights derived from our proprietary Human Response Platform™ will enable the potential development of therapies for biomarker-defined patient populations,” said Tuan

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 4, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 9, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.m. (ET) in Boston. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com.

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2013– AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results. “We are moving forward as an organization and are firmly focused on executing our revised business strategy,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “We continue to advance our programs in clinical development, including tivozanib